He had a history of depression. His medications were propranolol, indapamide, and amitriptyline.
The patient was referred to the acute admission unit and was discharged on a loading dose of warfarin (10 mg) and subcutaneous lowmolecular-weight heparin (enoxaparin 40 mg daily). He was advised to attend the anticoagulation clinic to maintain a tight control of his INR.
He presented 3 days later to the Accident and Emergency Department (A&E) with extensive swelling of the right leg and the inability to bear weight. A hematoma was suspected because his INR was 5.0; prothrombin time (PT) was 19.0 seconds. Warfarin and enoxaparin were stopped; he refused admission again but was advised to attend the day after for an urgent follow-up. The next day his INR was 4.6. On examination he had circumferential black/bluish discoloration of the right leg from the level of the knee to the lower third of the calf. There were no skin changes in the ankle and foot. A few fluid-filled blisters were present. The distal pulses were difficult to palpate, he had no tingling or numbness, and he did not have a drop foot. He was apyrexic, normotensive, and had a normal full blood cell count, urea, and electrolytes levels. His creatine kinase (CK) was 1293 U/L and his C-reactive protein (CRP) was 286 mg/L. (Normal ranges: INR 0.8-1.2, PT 8.0-12.0 seconds, CK 25-195 U/L, CRP <10 mg/L.)
He was admitted and subsequently underwent angiography of his right leg, which showed a long arterial occlusion involving the popliteal artery extending to the tibioperoneal trunk with 2 vessels run off. A right leg venogram showed extensive thrombosis of the venous system from common femoral to calf veins that was treated with thrombolysis over 24 hours via a catheter through his right femoral vein. There was some clinical and radiographic improvement following thrombolysis.
The cause of the thrombosis was yet unclear. Computed tomography of the abdomen, pelvis, and chest showed no malignancy and all tumor markers were negative. He received full IV heparinization with a noticeable clinical improvement in his right leg ( Fig. 1 ); its color had improved with less pain and swelling. Heparin was then stopped and the patient was discharged on 3 mg of warfarin daily.
Three days later he presented again to the A&E department with bluish-black discoloration of the right foot with decreased range of movement at the ankle joint but again with intact sensation, had no other complaints, and was otherwise systemically well; his INR then was 4.1. The right foot was cold, purple-black, and pulseless. The extensive necrotic ulceration of the right calf that was known from his previous admission had remained unchanged ( Fig. 2 ).
Warfarin-induced skin necrosis was suspected and warfarin immediately discontinued. Full IV heparinization was commenced. Vitamin K 10 mg was given IV to replenish all vitamin K-dependent factors. The diagnosis was supported by pre-vitamin K protein C level of 0.02 U/mL (normal range 0.7-1.4 U/mL) with normal protein S levels. Post vitamin K, the protein C level rose to 0.25 U/mL, suggestive of heterozygous congenital protein C deficiency. He did not have the factor V Leiden mutation. Two weeks later, the patient underwent surgical debridement of the right foot and leg. He was then discharged almost 10 weeks after his first admission on enoxaparin 1.5 mg/kg as the only anticoagulant. The patient was awaiting a belowknee amputation once the ulcer of the calf was healed. Three weeks later, the patient was re- admitted with severe abdominal pain, and angiography confirmed the clinical diagnosis of superior mesenteric artery thrombosis. Despite surgical intervention under cover of protein C concentrates, the patient did not survive the operation.
DISCUSSION
WISN was initially described in 1943 when a patient taking warfarin was noted to have necrotic changes of the skin (5) . In 1954, 13 cases of skin necrosis were reported that were associated with warfarin use (6) , but the first case of WISN in the English-language literature was not reported until 1961 (7) . WISN is still probably underreported and awareness of the condition is key to early diagnosis and minimization of morbidity and mortality.
Warfarin results in a decrease in the functional activity and synthesis of coagulant factors II, VII, IX, and X, in addition to a transient early decrease in levels of the naturally occurring anticoagulants protein C and S, through its action on vitamin K-dependent pathways. After warfarin is started, protein C rapidly decreases paralleling a fall in the level of factor VII. Factor IX falls more slowly, followed by factor X and protein S and finally factor II (8).
The exact pathologic mechanism underlying WISN remains unclear. Microvascular thrombosis, hypersensitivity to warfarin, and capillary hemorrhage, in addition to a direct toxic effect of warfarin, have all been suggested as potential mechanisms (3, 9) . However, the most likely mechanism involves thrombosis exacerbated by warfarin-induced deficiencies of naturally occurring anticoagulants, principally proteins C or S.
The involvement of protein C in WISN has been supported by the fact that protein C synthesis is blocked by warfarin and protein C activity decreases rapidly following the initiation of warfarin. Patients with heterozygous protein C deficiency are at greater risk of WISN (10, 11) and early replacement therapy with either vitamin K or protein C concentrate appears to block the lesion and aid in wound healing (12) .
Skin necrosis developed in our patient 3 days after the initiation of warfarin therapy on 2 occasions. WISN classically develops 3 to 6 days after starting warfarin in 93% of cases (13) ; however it has been reported as late as 18 months (14) . The clinical picture of WISN typically begins with a poorly demarcated erythematous tender patch that is often accompanied by soft tissue edema. Petechiae develop within a few hours that progress to ecchymosis and then large hemorrhagic bullae (8) . The development of these bullae signals irreversible injury and full-thickness skin necrosis is the inevitable end stage (6, 7, 9) .
The typical patient with WISN is said to be a middle-aged obese woman being treated for DVT or PE. However, cases involving male and female patients, children, patients with no VTE disease and even prophylactically anticoagulated patients can all be found in the literature. Seventy-five percent of WISN patients are being treated for DVT or PE (15) , skin necrosis rarely develops in those patients taking warfarin for cardiac indications such as atrial fibrillation (AF) or cerebral vascular disease (16) . This is likely to be because patients with VTE disease will already have lower protein C levels by virtue of consumption by the thrombosis, as well as inherited deficiency in some cases. Second, patients with AF anticoagulated with warfarin are rarely given large loading doses of warfarin so the imbalance between procoagulant and anticoagulant factors is less marked. In this case the effect of loading doses of warfarin in a patient subsequently found to have protein C deficiency were opposed only by prophylactic doses of enoxaparin, given in error, again allowing procoagulant effects to predominate.
The necrotic lesions can occur anywhere in the body, but they tend to localize to fatty areas such as the breast, thighs and buttocks (8) . In women, the most common site for the lesion to occur is the breast; however, the site of the lesion is unpredictable (1). In men involvement of the breast is rare; sometimes the penile skin may be affected (17) . There are few reports of patients whose lesions have healed spontaneously after the discontinuation of warfarin and they did not always reappear after warfarin treatment is recommenced (18) .
Once the necrotic changes have been recognized, warfarin therapy should be stopped immediately; despite the limited evidence that the discontinuation of warfarin changes the clinical course. Full IV heparinization should be initiated to prevent further thromboembolic events. Many advise the administration of vitamin K or fresh-frozen plasma to replenish rapidly the levels of protein C and S (18) . More than 50% of patients require surgical debridement (9) . Protein C concentrates have been used successfully to reduce bleeding risk during surgical intervention.
SUMMARY WISN poses a difficult diagnostic problem, knowledge of the condition allows early diagnosis. This case report highlights 2 important aspects: WISN can occur following the reintroduction of warfarin and warfarin-induced transient decreases in protein C levels in already deficient patients may contribute to the pathogenesis of WISN. The occurrence of these occasional cases should not, however, outweigh the vast evidence of the benefits of warfarin in the treatment and prevention of many potentially fatal diseases.
